twoXAR Pharmaceuticals has built a development portfolio targeting more than 18 different diseases. twoXAR’s unique approach to drug discovery combines steps from the traditional multi-step approach to R&D that severely limits the pace of drug discovery. This novel method – coupled with the company’s proprietary AI-driven platform – enables twoXAR to select a disease and initiate in vivo testing in months, instead of years.